MedTrace Logo

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

NCT03111121 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2025-07-20

Study results available
· View outcomes & findings →

Summary

Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure

Conditions

  • Microlaryngoscopy
  • Rigid Bronchoscopy

Interventions

DRUG

Sugammadex

receive reversal with sugammadex 4mg/kg

DRUG

neostigmine

receive reversal with neostigmine 0.04 mg/kg

DRUG

glycopyrrolate

receive reversal with glycopyrrolate (0.01 mg/kg)

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Pavithra Ranganathan, MD · West Virginia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-04
Primary Completion
2018-06-22
Completion
2019-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03111121 on ClinicalTrials.gov